Methylation profiles of hereditary and sporadic ovarian cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Histopathology

• Publication date

  2010-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1365-2559.2010.03642.xPMID 20840667
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas

  2009cited by this paper
• Hereditary breast cancer: from molecular pathology to tailored therapies

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer.

  2008cited by this paper
• High frequency of HIF-1α overexpression in BRCA1 related breast cancer

  2008cited by this paper
• Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer.

  2008cited by this paper
• Methylation profile in benign, borderline and malignant ovarian tumors

  2007cited by this paper
• MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas

  2007cited by this paper
• Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study

  2007cited by this paper
• Epigenetic gene silencing in cancer: the DNA hypermethylome.

  2007cited by this paper
• Age-Related DNA Methylation Changes in Normal Human Prostate Tissues

  2007cited by this paper
• Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data

  2006cited by this paper
• Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential

  2006cited by this paper
• EGFR Expression Predicts BRCA1 Status in Patients with Breast Cancer

  2006cited by this paper
• Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

  2006cited by this paper
• BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

  2005cited by this paper
• Promoter Hypermethylation Profile of Ovarian Epithelial Neoplasms

  2005cited by this paper
• Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations.

  2005cited by this paper
• Methylation-Specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences

  2005cited by this paper
• Origins and molecular pathology of ovarian cancer

  2005cited by this paper
• Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study

  2004cited by this paper
• Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

  2004cited by this paper
• Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

  2004cited by this paper
• Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers

  2004cited by this paper
• Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

  2004cited by this paper
• Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

  2004cited by this paper
• Gene silencing in cancer in association with promoter hypermethylation.

  2003cited by this paper
• Women harboring BRCA1/2 germline mutations are at risk for breast and female adnexal carcinoma.

  2003cited by this paper
• Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors

  2003cited by this paper
• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

  2003cited by this paper
• For and against - No consent should be needed for using leftover body material for scientific purposes - Against

  2002cited by this paper
• Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer

  2002cited by this paper
• Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.

  2002cited by this paper
• No consent should be needed for using leftover body material for scientific purposes. For.

  2002cited by this paper
• Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.

  2002cited by this paper
• Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes.

  2001cited by this paper
• DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis.

  2001cited by this paper
• Comparative Genomic Hybridization of Microdissected Familial Ovarian Carcinoma: Two Deleted Regions on Chromosome 15q Not Previously Identified in Sporadic Ovarian Carcinoma

  2001cited by this paper
• BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.

  2000cited by this paper
• Ovarian cancer: epidemiology, biology, and prognostic factors.

  2000cited by this paper
• Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

  2000cited by this paper
• Aberrant CpG-island methylation has non-random and tumour-type–specific patterns

  2000cited by this paper
• DNA hypermethylation in tumorigenesis: epigenetics joins genetics.

  2000cited by this paper
• Differences between hereditary and sporadic ovarian cancer.

  1999cited by this paper
• BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.

  1998cited by this paper
• Clinical and genetic evaluation of thirty ovarian cancer families.

  1998cited by this paper
• Aging and DNA methylation in colorectal mucosa and cancer.

  1998cited by this paper
• Molecular Cancer Dna Methylation Profiling of Ovarian Carcinomas and Their in Vitro Models Identifies Hoxa9, Hoxb5, Scgb3a1, and Crabp1 as Novel Targets

  year unknowncited by this paper

• TITLE : BRCA 1 promoter methylation and clinical outcomes in ovarian cancer : an individual patient data meta-analysis

  2021cites this paper
• Ovarian & endometrial cancers

  2021cites this paper
• Evaluation of the Diagnostic Potential of Candidate Hypermethylated Genes in Epithelial Ovarian Cancer in North Indian Population

  2021cites this paper
• BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer

  2020cites this paper
• BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis.

  2020cites this paper
• Identification of a four-gene methylation biomarker panel in high-grade serous ovarian carcinoma

  2020cites this paper
• Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives

  2019cites this paper
• Epigenetic Regulation of Adhesive Molecules in High-grade Serous Ovarian Carcinoma

  2019cites this paper
• DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.

  2018cites this paper
• Ubiquitylation and degradation of adenomatous polyposis coli by MKRN1 enhances Wnt/β-catenin signaling

  2018cites this paper
• Effect of hypermethylation in ovarian cancer: Computational approach

  2018cites this paper
• Importance of Cadherins Methylation in Ovarian Cancer: a Next Generation Sequencing Approach

  2018cites this paper
• The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer

  2018cites this paper
• A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?

  2018cites this paper
• Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients

  2017cites this paper
• Clinical significance of promoter hypermethylation of genes in ovarian cancer

  2017cites this paper
• Molecular mechanisms underlying the action of histone deacetylases inhibitors (HDACIs) in ovarian cancer

  2017cites this paper
• SiRNA and epigenetic aberrations in ovarian cancer.

  2016cites this paper
• DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification

  2016cites this paper
• Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in oligodendroglial tumors

  2016cites this paper
• Interplay of Epigenetics with Gynecological Cancer

  2016cites this paper
• Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy

  2016cites this paper
• Original article: DNA METHYLATION ASSESSMENT AS A PROGNOSTIC FACTOR IN INVASIVE BREAST CANCER USING METHYLATION-SPECIFIC MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION

  2016cites this paper
• Monitoring of DNA methylation in ovarian cancer using microarrays

  2015cites this paper
• Gene methylation of human ovarian carcinoma stromal progenitor cells promotes tumorigenesis

  2015cites this paper
• Modulatory effects of T-cadherin on cell behavior and growth factor receptor activity in carcinoma cells

  2014cites this paper
• Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status

  2014cites this paper
• DNA methylation profiles in ovarian cancer: Implication in diagnosis and therapy (Review)

  2014cites this paper
• Title Clinical characteristics of ovarian cancer classified by BRCA 1 , BRCA 2 , and RAD 51 C status Permalink

  2014cites this paper
• DNA Methylation Profiling Identifies EYA4 Gene as a Prognostic Molecular Marker in Hepatocellular Carcinoma

  2014cites this paper
• Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer

  2014cites this paper
• Promoter methylation of GATA4, WIF1, NTRK1 and other selected tumour suppressor genes in ovarian cancer.

  2013cites this paper
• Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.

  2013cites this paper
• Analyse globale des altérations abberantes de la méthylation de l'ADN dans le cancer de l'ovaire

  2013cites this paper
• Methylation analysis of tumor suppressor genes in endometroid carcinoma of endometrium using MS-MLPA.

  2013cites this paper
• Potential Tumor Biomarkers for Ovarian Cancer

  2012cites this paper
• Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.

  2012cites this paper
• Epigenetic biomarkers in the diagnosis of ovarian cancer.

  2012cites this paper
• Folate and choline metabolism gene variants in relation to ovarian cancer risk in the Polish population

  2012cites this paper
• Epigenetic modification and cancer: mark or stamp?

  2012cites this paper
• Promoter Methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma

  2012cites this paper
• Epigenetics in ovarian cancer.

  2012cites this paper
• Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer

  2012cites this paper
• Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA.

  2012cites this paper
• Chapter 4 – The role of PARP in DNA repair and its therapeutic exploitation

  2012cites this paper
• Aberrant expression of nuclear vimentin and related epithelial–mesenchymal transition markers in nasopharyngeal carcinoma

  2012cites this paper
• Folate and choline metabolism gene variants in relation to ovarian cancer risk in the Polish population

  2012cites this paper
• Response to the Letter to the Editor by Bol and van Diest regarding the review article “BRCA1 methylation and BRCA1 mutations in ovarian cancer”

  2011cites this paper
• BRCA1 methylation and BRCA1 mutations in ovarian cancer.

  2011cites this paper
• Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer

  2011cites this paper
• Metylácia vybraných tumor-supresorických génov v benígnych a malígnych ovariálnych nádoroch Methylation of selected tumor-supressor genes in benign and malignant ovarian tumors

  2011cites this paper
• The role of PARP in DNA repair and its therapeutic exploitation

  2011cites this paper
• SLIT2 is epigenetically silenced in ovarian cancers and suppresses growth when activated.

  2011cites this paper
• Methylation markers for early breast cancer detection

  2010cites this paper
• Low Levels of BNIP3 Promoter Hypermethylation in Invasive Breast Cancer

  2010cites this paper